Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (3): 197-207     DOI: 10.3909/ricm0726
Review | Next articles
Utilization of Galectin-3 in Case Management Across the Spectrum of Heart Failure
Peter McCullough1, Rudolph A. de Boer2, Frank Edelmann3, Connie M. Lewis4, Alan S. Maisel5
1 Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hosital, Dallas, TX, The Heart Hospital, Plano TX
2 Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
3 Department of Cardiology, University of Göttingen, German Center for Cardiovascular Research, Göttingen Division of Cardiology, Germany
4 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
5 San Diego Veterans Affairs Medical Center, San Diego, CA
Download:  PDF(1579KB)  ( 165 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
In patients with heart failure as a result of mechanical and neurohormonal derangements, macrophages secrete galectin-3, which is a paracrine and endocrine factor that stimulates additional macrophages, pericytes, myofibroblasts, and fibroblasts to proliferate and secrete procollagen I, which is irreversibly crosslinked to form fibrotic collagen. Normal plasma concentrations of galectin-3 are < 11.0 ng/mL. Galectin-3 measured in blood has been shown to predict the development of all-cause mortality and heart failure in the general population, identify increased risk for de novo heart failure and progressive loss of renal filtration function in healthy middle-aged adults, predict cardiac failure in patients after acute coronary syndromes, help establish the diagnosis of heart failure with preserved ejection fraction in patients presenting with effort intolerance, and aid in the prognosis of both systolic and nonsystolic heart failure for the outcomes of hospitalization and death. This article presents case discussions of these applications to highlight the importance of galectin-3 measurement across the spectrum of patients at risk for cardiorenal disease.
Key words:  Galectin-3      Heart failure      Chronic kidney disease      Biomarker      Medical management      Hospitalization      Mortality     
Published:  30 September 2014     

Cite this article: 

Peter McCullough, Rudolph A. de Boer, Frank Edelmann, Connie M. Lewis, Alan S. Maisel. Utilization of Galectin-3 in Case Management Across the Spectrum of Heart Failure. Reviews in Cardiovascular Medicine, 2014, 15(3): 197-207.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0726     OR     https://rcm.imrpress.com/EN/Y2014/V15/I3/197

[1] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[2] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[3] Chiara Minà, Laura Ajello, Gabriele Di Gesaro, Calogero Falletta, Francesco Clemenza. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 241-252.
[4] Peter A. McCullough, John Eidt, Janani Rangaswami, Edgar Lerma, James Tumlin, Kevin Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Sandeep Soman, Bhupinder Singh, Sean P. McCullough, Haley B. McCullough, Alberto Palazzuoli, Gaetano M. Ruocco, Claudio Ronco. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 1-7.
[5] Amir Kazory, Maria Rosa Costanzo. The dynamic relationship between serum chloride and cardiorenal syndrome[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 25-29.
[6] Megan S. Joseph, Maryse Palardy, Nicole M. Bhave. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 31-39.
[7] Xiaogen Chen, Chunna Jin, Lan Xie, Meixiang Xiang. LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 113-118.
[8] Akanksha Agrawal, Hafeez Ul Hassan Virk, Iqra Riaz, Deepanshu Jain, Byomesh Tripathi, Chayakrit Krittanawong, Benham Bozorgnia, Vincent Figueredo, Peter A. McCullough, Janani Rangaswami. Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 123-127.
[9] Ya Wang, Wen-Jing Sun, Ze-Sheng Ji, Chong-Bin Liu, Rui Wang. Serum albumin and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 139-145.
[10] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[11] Hesam Mostafavi Toroghi, Kevin Bryan Lo, Mary Rodriguez Ziccardi, Benjamin Horn, Napatt Kanjanahattakij, Erum Malik, Jorge Penalver, Janani Rangaswami, Shuchita Gupta, Aman Amanullah. Renal implications of pulmonary arterial capacitance in acute heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 267-272.
[12] Girish Singhania, Abutaleb A. Ejaz, Peter A. McCullough, Aaron Y. Kluger, Saravanan Balamuthusamy, Bhagwan Dass, Namrata Singhania, Adhish Agarwal. Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 111-120.
[13] Wan Chin Hsieh, Anas Aboud, Brandon M. chael Henry, Mohamed Omara, Jaroslav Lindner, Jan Pirk. Serum albumin in patients undergoing transcatheter aortic valve replacement: A meta-analysis[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 161-169.
[14] Victoria E. Tril, Alla V. Burlutskaya, Lily V. Polischuk. Metabolic cardiomyopathy in pediatrics[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 73-80.
[15] Janani Rangaswami, Sandeep Soman, Peter A. McCullough. Key updates in Cardio-Nephrology from 2018: springboard to a bright Future[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 113-116.
No Suggested Reading articles found!